Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Université de Montréal
$105,000.00
Discovering optimal targets for adoptive T-cell immunotherapy of leukemia
EF 2011-12
Résumé
More than 100,000 individuals treated for hematological malignancies owe their life to allogeneic hematopoietic cell transplantation (AHCT). Cure of leukemias by AHCT is due mainly to the graft-versus-leukemia (GVL) effect, in which tumor cells are eradicated by the donor T-cells. In this form of cancer immunotherapy, donor lymphocytes are neither selected nor activated prior to transfer. Unfortunately, this creates two major problems. First, 60% of graft recipients suffer from graft-versus-host disease (GVHD), a disease often lethal but always incapacitating. Second, donor T-cells that have not been activated can be tolerized by tumor cells, resulting in an attenuated form of GVL. These two caveats can be circumvented by the injection of activated antigen-specific CD8 T-cells. Antigens that are recognized by T cells are generated by the interplay of protein synthesis and protein degradation. The peptides generated within the cells are exported at the cell surface for immune recognition.
Two types of antigens can be targeted for antigen-specific immunotherapy: 1) Antigens that are present only on cancer cells compared to their normal counterpart (TAAs) and 2) Antigens that arise from inter-individual variations in the genome that translate to differential peptide expression at the cell surface (MiHAs). Several studies in humans have demonstrated independently the value of TAA- and MiHA-specific T-cells for eradication of solid tumors and leukemia, respectively. Importantly, the value of TAAs and MiHAs as target for antigen-specific cancer immunotherapy has never been assessed against the same tumor. In this study, our main goal is to directly compare the therapeutic efficacy of T-cells targeted to these two types of antigens. We believe that the crucial insights gained from our studies will serve a guide for selecting the best antigens for antigen-specific leukemia immunotherapy in humans.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
257560
Name
Vincent Krystel
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Discovering optimal targets for adoptive T-cell immunotherapy of leukemia
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Antigen Regognition; Cancer; Cellular Biology; Immunotherapy; Mhc I; Peptide; T Lymphocyte Function; Transplantation
Abstract
More than 100,000 individuals treated for hematological malignancies owe their life to allogeneic hematopoietic cell transplantation (AHCT). Cure of leukemias by AHCT is due mainly to the graft-versus-leukemia (GVL) effect, in which tumor cells are eradicated by the donor T-cells. In this form of cancer immunotherapy, donor lymphocytes are neither selected nor activated prior to transfer. Unfortunately, this creates two major problems. First, 60% of graft recipients suffer from graft-versus-host disease (GVHD), a disease often lethal but always incapacitating. Second, donor T-cells that have not been activated can be tolerized by tumor cells, resulting in an attenuated form of GVL. These two caveats can be circumvented by the injection of activated antigen-specific CD8 T-cells. Antigens that are recognized by T cells are generated by the interplay of protein synthesis and protein degradation. The peptides generated within the cells are exported at the cell surface for immune recognition.
Two types of antigens can be targeted for antigen-specific immunotherapy: 1) Antigens that are present only on cancer cells compared to their normal counterpart (TAAs) and 2) Antigens that arise from inter-individual variations in the genome that translate to differential peptide expression at the cell surface (MiHAs). Several studies in humans have demonstrated independently the value of TAA- and MiHA-specific T-cells for eradication of solid tumors and leukemia, respectively. Importantly, the value of TAAs and MiHAs as target for antigen-specific cancer immunotherapy has never been assessed against the same tumor. In this study, our main goal is to directly compare the therapeutic efficacy of T-cells targeted to these two types of antigens. We believe that the crucial insights gained from our studies will serve a guide for selecting the best antigens for antigen-specific leukemia immunotherapy in humans.
Competitiondate
201110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Vincent, Krystel
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~